

Module 3: Regulatory Requirements for a New Active Substance: Quality  
10th Feb 2026 – 12th Feb 2026,



Nhow Hotel in Frankfurt, Brüsseler Str. 1-3, 60327 Frankfurt am Main

**Module Leader(s): Christian Maasch**

**Date:** Tuesday 10<sup>th</sup> Feb

Time	Activity	Speaker
<b>13.00</b>	Registration	
<b>13.15 – 13.30</b>	Welcome & Introduction to Module 3	<b>Christian Maasch</b> <b>Takeda</b>
<b><i>Management in Regulatory Affairs</i></b>		
<b>13.30 – 14.30</b>	Lecture 1: CMC in the Drug Development Programme	<b>Ruxandra Ionescu</b> <b>ProPharma Group</b>
<b>14.30 - 15.00</b>	Refreshment Break	
<b>15.00 – 16.00</b>	Lecture 2: API Manufacture and In-Process Controls	<b>Ruxandra Ionescu</b> <b>ProPharma Group</b>
<b>16.00 – 17.00</b>	Lecture 3: Nomenclature and Characterisation of the Active Ingredient	<b>Christian Maasch</b> <b>Takeda</b>
<b>17.00 – 18.00</b>	Lecture 4: CMC Project Management	<b>Christian Maasch</b> <b>Takeda</b>

Module 3: Regulatory Requirements for a New Active Substance: Quality  
10th Feb 2026 – 12th Feb 2026,



**Date:** Wednesday 11<sup>th</sup> Feb

Time	Activity	Speaker
<b>09.00 – 10.00</b>	Lecture 5: Analytical Methods and Validation	<b>In-person or remote</b> <b>Eurofins</b>
<b>10.00 – 10.30</b>	Refreshment Break	
<b>10.30 – 11.30</b>	Lecture 6: Developing Specifications for the Active Ingredient	<b>Christian Maasch</b> <b>Takeda</b>
<b>11.30 – 12.30</b>	Lecture 7: Pharmaceutical Development and Manufacture of the Drug Product	<b>Torsten Kneuss</b> <b>Bayer</b>
<b>12.30 – 13.30</b>	<b>LUNCH</b>	
<b>13.30 – 15.30</b>	Case Study 1 with discussions and presentations	<b>Christian Maasch,</b> <b>Torsten Kneuss ,</b> <b>other Speakers</b>
<b>15.30 – 16.00</b>	Refreshment Break	
<b>16.00 – 17.00</b>	Lecture 8: Stability of the Drug product	<b>Torsten Kneuss</b> <b>Bayer</b>

Module 3: Regulatory Requirements for a New Active Substance: Quality  
10th Feb 2026 – 12th Feb 2026,



**Date:** Thursday 12<sup>th</sup> Feb

<b>09.00 – 10.00</b>	Lecture 8: Pharmaceutical Packaging	<b>Torsten Kneuss</b> <b>Bayer</b>
<b>10.00 – 10.30</b>	Refreshment break	
<b>10.30 – 12.00</b>	Case Study 2 (Packaging)	<b>Torsten Kneuss &amp; Christian Maasch</b>
<b>12.00 – 13.00</b>	Lecture 9: Good Manufacturing Practice – Clinical Supply and Regulatory Considerations	<b>Simona Riedel,</b> <b>VfA, German Association of Research-Based Pharmaceutical Companies.</b>
<b>13.00 – 13.30</b>	<b>LUNCH</b>	
<b>13.30 – 14.30</b>	Lecture 10: How AI and digitalization are reshaping Regulatory CMC Managers' work – an industry and regulator viewpoint Regulatory	<b>David Boutellier</b> <b>REMATIQ</b>
<b>14.30-15.00</b>	Lecture 11: Agency Perspective and Closing	<b>Christian Maasch,</b> <b>all</b>

Module 3: Regulatory Requirements for a New Active Substance: Quality  
10th Feb 2026 – 12th Feb 2026,



DRAFT

Module 3: Regulatory Requirements for a New Active Substance: Quality

10th Feb 2026 – 12th Feb 2026,



DPAF